Answer to Question #12110 Submitted to "Ask the Experts"
Category: Pregnancy and Radiation
The following question was answered by an expert in the appropriate field:
If a patient who is breast-feeding her child receives indium-111 (111In) octreotide, should she interrupt breast-feeding for a certain length of time? Also if a patient receives 111In diethylenetriaminepentaacetic acid (DTPA) for a colon transit study, should breast-feeding be interrupted?
It appears that breast-feeding does not need to be interrupted for either of these radiopharmaceuticals. According to Regulatory Guide 8.39 Release of Patients Administered Radioactive Materials, the U.S. Nuclear Regulatory Commission does not require interruption of breast-feeding for 111In octreotide or 111In DTPA. Either these radiopharmaceuticals are not excreted in breast milk, or the activity that is routinely administered is less than the activity that would give a measurable dose of radiation to the infant.
Certified Medical Health Physicist